BMC Pulmonary Medicine最新文献

{"title":"Hsa-miR-21 promoted the progression of lung adenocarcinoma by regulating LRIG1 expression.","authors":"Li Liu, Xinhua Liu, Chengpeng Gao, Meijuan Liu, Mengmeng Peng, Leqiang Wang","doi":"10.1186/s12890-025-03620-1","DOIUrl":"https://doi.org/10.1186/s12890-025-03620-1","url":null,"abstract":"<p><p>Lung cancer is the foremost cause of cancer-related fatalities globally, and lung adenocarcinoma (LUAD) is one of the common types of lung cancer with significant molecular heterogeneity. Leucine rich repeats and immunoglobulin like domains 1 (LRIG1) has been demonstrated to be down-regulated in lung cancer and related to prognosis of patients. The purpose of this work is to explore the targeting miRNAs of LRIG1, and the related regulatory mechanisms in LUAD. The data of LUAD patients were collected from The Cancer Genome Atlas and Gene Expression Omnibus databases. The differential expression analysis and gene set enrichment analysis (GSEA) were performed using \"limma\" and \"clusterProfiler\" function package, respectively. The levels of hsa-miR-21 mRNA and LRIG1 mRNA and LRIG1 protein expressions were analyzed using RT-qPCR and western blot analysis. The infiltration of immune cells was determined using CIBERSORT software. In LUAD patients, hsa-miR-21 expression was observably related to LRIG1 expression. Hsa-miR-21 might negatively modulate the LRIG1 expression in LUAD. LUAD patients with hsa-miR-21 up-regulation exhibited inferior prognosis. In addition, those with LUAD who had high hsa-miR-21 expression but low LRIG1 expression had a worse prognosis, whereas those with low hsa-miR-21 expression but high LRIG1 expression had a better prognosis. Functional enrichment analysis indicated that metabolic related signaling pathways (EGFR tyrosine kinase inhibitor resistance) were significantly activated in LUAD patients with LRIG1 up-regulation. Finally, we found that relative content of naive B cells, plasma cells and resting CD4 + T cells were significantly increased and regulatory T cells and Macrophages M0 were decreased in LRIG1 high expression group and hsa-miR-21 low expression group. We firstly reported that hsa-miR-21 might regulate the LRIG1 expression in LUAD, thereby effecting the onset and progression of LUAD. Clinical trial number: Not applicable.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"189"},"PeriodicalIF":2.6,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12016109/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143954359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic value of multivariate logistic regression analysis and amyloid A lactate monitoring in patients with severe pneumonia-associated sepsis.","authors":"Mengying Xie, Zuliang Min, Wei Jiang, Zhifang He, Xuexia Xia","doi":"10.1186/s12890-025-03648-3","DOIUrl":"https://doi.org/10.1186/s12890-025-03648-3","url":null,"abstract":"<p><strong>Background: </strong>Patients with severe pneumonia-associated sepsis often face high mortality rates, highlighting the need for simple and effective prognostic biomarkers. This study aimed to investigate the prognostic significance of serum amyloid A (SAA) and blood lactate (Lac) levels using multivariate logistic regression.</p><p><strong>Method: </strong>This was a retrospective study conducted from January 2021 to December 2023, which included 156 patients diagnosed with severe pneumonia. Of these, 54 developed sepsis (septic group) while 102 did not (non-septic group). Clinical data, SAA, and Lac levels were compared between the groups. Multivariate logistic regression was employed to identify factors influencing the onset of severe pneumonia-associated sepsis and to assess the prognostic significance of SAA and Lac.</p><p><strong>Result: </strong>Significant differences were found in APACHE II score, SOFA score, age, mechanical ventilation, SAA, and Lac levels between the septic and non-septic groups (P < 0.05). Logistic regression analysis identified age, SOFA score, APACHE II score, mechanical ventilation, SAA, and Lac as influencing factors for severe pneumonia-associated sepsis (P < 0.05). Patients with poor prognosis (PP) had significantly elevated SAA and Lac levels compared to those with good prognosis (GP) (P < 0.05). Among septic patients, those with PP had significantly higher SAA and Lac levels compared to those with GP (P < 0.05). Multivariate logistic regression revealed that advanced age, septic shock, elevated SAA levels, and increased Lac levels were predictors of PP (P < 0.05). The prognostic value of SAA and Lac was demonstrated by AUCs of 0.764 and 0.771, respectively. When combined, the AUC increased to 0.903 with a specificity of 95.00% and sensitivity of 80.25%.</p><p><strong>Conclusion: </strong>Severe pneumonia-associated sepsis is influenced by age, SOFA score, APACHE II score, mechanical ventilation, SAA, and Lac levels. Elevated SAA and Lac levels are associated with PP and can provide prognostic information for adverse outcomes. While SAA and Lac show potential as biomarkers for predicting the prognosis of severe pneumonia-associated sepsis, their clinical utility should be considered in conjunction with other diagnostic and clinical factors for effective patient management and risk stratification.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"191"},"PeriodicalIF":2.6,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12020197/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143961564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stereotactic body radiation therapy and thermal ablation for treatment of patients with pulmonary metastases: a systematic literature review and meta-analysis.","authors":"Paul Laeseke, Calvin Ng, Nicole Ferko, Andrada Naghi, George W J Wright, Di Wang, Alyshia Laidlaw, Iftekhar Kalsekar, Tony Amos, Balaji Laxmanan, Sudip K Ghosh, Meijia Zhou, Philippe Szapary, Michael Pritchett","doi":"10.1186/s12890-025-03561-9","DOIUrl":"https://doi.org/10.1186/s12890-025-03561-9","url":null,"abstract":"<p><strong>Objective: </strong>To compare local tumor progression (LTP) and overall survival (OS) after image-guided thermal ablation (IGTA; microwave/radiofrequency ablation) versus stereotactic body radiation therapy (SBRT) in patients with pulmonary metastases.</p><p><strong>Methods: </strong>A systematic literature review was performed to capture studies that used IGTA or SBRT for patients with pulmonary metastases and studies that reported one, two, and threeyear LTP/OS were included. Patients with pulmonary metastases, and a subgroup with metastases from colorectal or renal cell carcinoma, or sarcoma (termed subgroup) which are considered more radioresistant, were analyzed. Single-arm pooled analyses, univariable, and multivariable random-effects meta-regressions were conducted to compare LTP and OS between IGTA and SBRT treated patients.</p><p><strong>Results: </strong>Analyses included 3,264 IGTA and 5,486 SBRT patients. IGTA patients with pulmonary metastases had higher LTP than SBRT patients at one year, 13% and 9% respectively. At two years, the LTP for IGTA patients was 14% compared to 16% for SBRT patients. Three-year LTP remained lower for IGTA patients compared to SBRT patients (14% and 22% respectively). In the subgroup, SBRT patients had higher LTP than IGTA patients across all timepoints. OS was similar across analyses/subgroups in the single-arm pooled analyses. The multivariable analyses showed that SBRT was associated with significantly lower OS at one year; however nonsignificant differences were observed at years two and three.</p><p><strong>Conclusions: </strong>In patients with pulmonary metastases, IGTA had lower LTP than SBRT at later timepoints. In patients with colorectal, renal cell carcinoma, or sarcoma pulmonary metastases, LTP was similar to overall LTP for IGTA, while it was higher for SBRT.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"188"},"PeriodicalIF":2.6,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12016196/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143965221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impostor of chest pain: a case of lung cancer mimicking angina.","authors":"Dingshan Zhang, Mingtai Chen, Xin Zhou, Yanneng Xu, Yiwei Zeng, Xiaoqin Luo, Ping Liu, Lingling Liang, Yunmei Qian, Gang Luo, Yan Jiang, Mengnan Liu","doi":"10.1186/s12890-025-03663-4","DOIUrl":"https://doi.org/10.1186/s12890-025-03663-4","url":null,"abstract":"<p><p>Chest pain is a common symptom with a complex etiology involving multiple organs and systems. Cardiovascular, digestive and respiratory diseases can cause chest pain. A single condition usually reformulates and can cause this symptom, but a combination of conditions can also cause it. This case reports a 69-year-old male suffered from recurrent chest pain. Coronary heart disease, gastroesophageal reflux disease and left lung adenocarcinoma were diagnosed successively for nearly 1 year. The patients focus on one disease, and the medical staff neglects to deal with multiple diseases simultaneously. Ambiguous evidence and patients' unmotivated attitudes towards treatment make early diagnosis of lung cancer difficult. Treatment for coronary heart disease and gastroesophageal reflux disease masks the symptoms of lung cancer to some extent, resulting in a skewed diagnostic focus. This report highlights the need for clinicians to improve communication with patients to enhance treatment adherence and provide comprehensive screening, identification, and treatment of chest pain etiologies to prevent delays in patient treatment. The findings also suggest that awareness of the therapeutic and prognostic impact of interstitial lung disease on lung cancer should be improved, which is essential for the development of clinical treatment protocols.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"194"},"PeriodicalIF":2.6,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12020168/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143976583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of 5% sodium bicarbonate and 10% sodium chloride as contrast agents for lung perfusion with electrical impedance tomography: a prospective clinical study.","authors":"Yelin Gao, Yuecheng He, Yi Chi, Siyi Yuan, Songlin Wu, Yun Long, Zhanqi Zhao, Huaiwu He","doi":"10.1186/s12890-025-03665-2","DOIUrl":"https://doi.org/10.1186/s12890-025-03665-2","url":null,"abstract":"<p><strong>Introduction: </strong>This study aimed to compare sodium bicarbonate (NaHCO₃) and sodium chloride (NaCl) as contrast agents for regional lung perfusion imaging with electrical impedance tomography in critically ill patients with respiratory failure.</p><p><strong>Methods: </strong>15 mL 5% NaHCO₃ and 10 mL 10% NaCl were sequentially administered in all the enrolled patients with respiratory failure. EIT maps were divided into four cross-regions: upper right (UR), upper left (UL), lower right (LR), and lower left (LL).</p><p><strong>Result: </strong>A total of 20 pair bolus injections from 16 mechanically ventilated patients were obtained. Compared to NaHCO₃, NaCl caused a larger drop of maximum impedance amplitude after the bolus injection (1276 ± 329 vs. 509 ± 159 AU, P < 0.001). Regional perfusion distribution (%) of four cross-regions between two indicators were significantly correlated (R² = 0.90 for regional perfusion%, p < 0.001; R² = 0.93 for regional ventilation/perfusion matching, p < 0.001) in 80 pair measurements. The Bland-Altman analysis showed a strong overall agreement in regional perfusion distribution (%) [mean bias 0.09% (95% confidence interval, CI: -0.91%, 1.09%), lower limits of agreement (LOA) -8.03% (95% CI: -9.75%, -6.31%), upper LOA 8.21% (95% CI: 6.48%, 9.93%)] between indicators in 80 pair measurements.</p><p><strong>Conclusion: </strong>EIT with NaHCO₃ as a contrast agent yields a high agreement of regional lung perfusion compared to NaCl in critically ill patients with respiratory failure.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"190"},"PeriodicalIF":2.6,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12016440/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143961656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterization of the Mmalton carrier's cohort within the EARCO (European Alpha- 1 Antitrypsin Research Collaboration) registry.","authors":"Beatriz D Ferraz, Maria Sucena, Margarida Fonseca Cardoso, Alice M Turner, José María Hernández-Pérez, María Torres-Duran, Hanan Tanash, Carlota Rodríguez-García, Jens-Ulrik Jensen, Angelo Corsico, José Luis López-Campos, Kenneth Chapman, Christian F Clarenbach, Joana Gomes, Marc Miravitlles, Beatriz Lara","doi":"10.1186/s12890-025-03651-8","DOIUrl":"https://doi.org/10.1186/s12890-025-03651-8","url":null,"abstract":"<p><strong>Introduction: </strong>The PI*Mmalton variant is a rare form of alpha-1-antitrypsin (AAT) deficiency, caused by a mutation in the SERPINA1 gene and associated with reduced AAT levels. Its clinical significance remains uncertain due to the limited number of reported cases.</p><p><strong>Methods: </strong>This study characterizes PI*Mmalton carriers within the EARCO (European Alpha-1 Antitrypsin Research Collaboration) registry and compares them with PI*ZZ individuals. Patients were categorized into moderate PI*Mmalton (combined with PI*S or PI*I) and severe PI*Mmalton (combined with PI*Z, PI*Mmalton, PI*MProcida, or PI*MHerleen). Demographic data, lung function, respiratory symptoms, disease prevalence, and augmentation therapy use were analyzed.</p><p><strong>Results: </strong>Among 2074 individuals, 59 (2.8%) carried a PI*Mmalton allele. Severe PI*Mmalton patients exhibited lung function impairment comparable to PI*ZZ individuals, with a significantly lower FEV₁/FVC ratio (55.9% vs. 57.6%) and similar AAT levels (~ 25 mg/dL). Moderate PI*Mmalton patients had better lung function and higher AAT levels (median 54 mg/dL). Emphysema was more prevalent in severe PI*Mmalton (54.5%) and PI*ZZ (61.2%) than in moderate PI*Mmalton (34.6%). Augmentation therapy use was highest in severe PI*Mmalton (45.2%). Liver disease prevalence was comparable across groups.</p><p><strong>Conclusion: </strong>Severe PI*Mmalton patients exhibit clinical and functional similarities to PI*ZZ individuals, suggesting a comparable disease burden. Moderate PI*Mmalton patients, however, show milder impairment. These findings reinforce the need for genotype-specific management strategies and suggest that PI*Mmalton carriers, particularly those with severe variants, should be considered in future clinical trials.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"187"},"PeriodicalIF":2.6,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12016053/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143959565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role and clinical significance of myeloperoxidase (MPO) and TNF-α in prognostic evaluation of T-COPD.","authors":"E Jiang, Yingya Fu, Yalin Wang, Li Ying, Wen Li","doi":"10.1186/s12890-025-03655-4","DOIUrl":"https://doi.org/10.1186/s12890-025-03655-4","url":null,"abstract":"<p><strong>Purpose: </strong>Chronic obstructive pulmonary disease (COPD) is a progressive inflammatory disorder that requires effective biomarkers for assessing disease activity and severity. This study aimed to compare clinical characteristics, inflammatory biomarker levels, and pulmonary function between stable COPD (S-COPD) and treated COPD (T-COPD) patients, with a focus on the prognostic value of inflammatory markers such as TNF-α, MPO, and IL-6.</p><p><strong>Methods: </strong>A total of 81 patients were enrolled in the study, including 39 with stable COPD (S-COPD) and 42 with treated COPD (T-COPD). Clinical characteristics, lung function (measured by FEV1%), and inflammatory biomarkers (IL-6, MMP-9, SAA, MPO, TNF-α, and others) were assessed. Inflammatory biomarkers were compared between the two groups, and their associations with pulmonary function were examined using correlation and regression analyses. Prognostic value was assessed using ROC curve analysis.</p><p><strong>Results: </strong>The T-COPD group exhibited significantly more severe disease, with higher rates of exacerbations, worse quality of life (CAT and mMRC scores), and reduced lung function (FEV1%, 6-minute walk distance). Inflammatory biomarker analysis revealed no significant differences for IL-6, MMP-9, SAA, RDW, LCN2, PLR, and NLR, but TNF-α and MPO were significantly higher in T-COPD patients (P = 0.015 and P = 0.012, respectively). Among these biomarkers, MPO and TNF-α showed strong negative correlations with FEV1% in T-COPD patients (r = -0.521 and r = -0.459, respectively). ROC curve analysis indicated that TNF-α (AUC = 0.821) was the most predictive biomarker, followed by MPO (AUC = 0.785) and IL-6 (AUC = 0.711). Combining TNF-α and MPO provided the best prognostic performance (AUC = 0.878).</p><p><strong>Conclusion: </strong>TNF-α, MPO, and IL-6 are significant biomarkers associated with disease severity and pulmonary function in T-COPD patients. The combination of TNF-α and MPO offers superior prognostic value, suggesting that these biomarkers may serve as useful tools for monitoring disease progression and guiding treatment decisions in treated COPD patients.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"192"},"PeriodicalIF":2.6,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12020186/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143972576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Polypharmacy and potentially inappropriate medication (PIM) use among older veterans with idiopathic pulmonary fibrosis (IPF) - a retrospective cohort study.","authors":"Daniel M Guidot, Marc Pepin, S Nicole Hastings, Robert Tighe, Kenneth Schmader","doi":"10.1186/s12890-025-03611-2","DOIUrl":"https://doi.org/10.1186/s12890-025-03611-2","url":null,"abstract":"<p><strong>Background: </strong>Idiopathic pulmonary fibrosis (IPF) is a deadly respiratory disease of older patients. IPF therapies (antifibrotics) are efficacious in slowing disease progression, but they are critically underutilized. Potential barriers to antifibrotic use are polypharmacy and potentially inappropriate medications (PIM). We examined the frequency of these factors for older patients with IPF.</p><p><strong>Methods: </strong>We retrospectively analyzed records of Veterans ≥ 65 years old in the Durham Veterans Affairs Health Care System who received a diagnosis of IPF and received care between 11 April 2023 and 9 September 2024. We analyzed medication profiles from the Corporate Data Warehouse including total medication counts, polypharmacy (≥ 5 medications), severe polypharmacy (> 15 medications), and prescription of a PIM in the anticholinergic, antidepressant, sedative, and antipsychotic classes using published geriatric guidelines (2023 Beers criteria, Screening Tool of Older People's Potentially Inappropriate Prescriptions [STOPP] version 3). Identified PIMs underwent protocolized review to categorize them further as likely appropriate or inappropriate.</p><p><strong>Results: </strong>We identified 367 Veterans ≥ 65 years old with a diagnosis of IPF diagnostic during our study period. Total medication count was high for older Veterans (mean 14.2, SD 7.0). Veterans commonly had polypharmacy (350/367, 95.4%), severe polypharmacy (161/367, 43.9%), and ≥ 1 PIM (97/367, 26.4%). After protocolized review, 5.7% (21/367) of older Veterans with IPF had a likely inappropriate medication without documentation of a failed preferred alternative.</p><p><strong>Conclusion: </strong>For older Veterans with IPF, polypharmacy and PIM use were common and represent likely barriers to effective IPF pharmacotherapy initiation. Interventions that target these factors like deprescribing could improve antifibrotic use.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"186"},"PeriodicalIF":2.6,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12012958/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143965177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of home noninvasive positive pressure ventilation combined with pulmonary rehabilitation on dyspnea severity and quality of life in patients with severe stable chronic obstructive pulmonary disease combined with chronic type II respiratory failure: a randomized controlled trial.","authors":"Shu Xie, Xiaoping Li, Yanfeng Liu, Jian Huang, Fangying Yang","doi":"10.1186/s12890-025-03656-3","DOIUrl":"https://doi.org/10.1186/s12890-025-03656-3","url":null,"abstract":"<p><strong>Background: </strong>Chronic obstructive pulmonary disease (COPD) is a progressive respiratory condition that significantly affects patients' quality of life. Non-invasive positive pressure ventilation (NPPV) and pulmonary rehabilitation have both shown promise in improving symptoms and lung function in COPD patients. However, the combined effects of home-based pulmonary rehabilitation and NPPV on moderate to severe COPD patients remain unclear.</p><p><strong>Objective: </strong>This study aimed to evaluate the efficacy of home pulmonary rehabilitation combined with non-invasive positive pressure ventilation (CPRNG group) compared to conventional treatment (CTG group) in patients with moderate to severe COPD.</p><p><strong>Methods: </strong>A total of 269 patients with moderate to severe COPD were enrolled, with 137 patients in the CTG group and 132 in the CPRNG group. The primary outcome measures included the COPD assessment test (CAT) score, modified medical research council scale (mMRC) score, forced expiratory volume in one second (FEV₁) percentage, 6-min walk test, and arterial oxygen pressure (PaO₂). Secondary outcomes included various dimensions of quality of life (impact, symptoms, and activity) measured through patient-reported outcomes.</p><p><strong>Results: </strong>Baseline comparisons between groups showed no significant differences in sociodemographic characteristics, disease duration, or symptoms. The CPRNG group showed significant improvements compared to the CTG group in the CAT score (p = 0.028), mMRC score (p = 0.015), FEV1% (p = 0.008), 6-min walk test (p = 0.001), and PaO₂ (p < 0.001). Additionally, improvements in impact, symptoms, activity, and overall scores were significantly better in the CPRNG group (p < 0.05).</p><p><strong>Conclusions: </strong>Home pulmonary rehabilitation combined with non-invasive positive pressure ventilation significantly improves multiple dimensions of quality of life, particularly in controlling symptoms and enhancing daily activities in COPD patients. This combined therapy proves to be an effective treatment strategy, offering notable benefits in lung function, exercise capacity, and overall quality of life in COPD patients.</p><p><strong>Trial registration: </strong>The clinical trial was registered retrospectively on the Chinese Clinical Trial Registry (ChiCTR, www.chictr.org.cn ID: ChiCTR2500096605) on 2025-01-26, as required by The Fourth Hospital of Institutional (Changsha Fourth Hospital, Hunan Province, China) Review Board guidelines. Ethics approval date: January 2023 to December 2025.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"185"},"PeriodicalIF":2.6,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12013138/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143972672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical features and survival analysis of adult patients with severe lower respiratory tract infection positive for respiratory syncytial virus.","authors":"Jiahua Tian, Ling Zhang, Xunling Wang, Guichuan Huang, Zhu Li, Ling Gong, Daishun Liu","doi":"10.1186/s12890-025-03660-7","DOIUrl":"https://doi.org/10.1186/s12890-025-03660-7","url":null,"abstract":"<p><strong>Background: </strong>The awareness and attention toward lower respiratory tract infections caused by respiratory syncytial virus (RSV) are lower in adults than in children. Moreover, the clinical data on severe RSV infections in adults are lacking. This study aimed to augment the clinical understanding of RSV infections.</p><p><strong>Method: </strong>This study was performed on 191 adult patients with severe lower respiratory tract infections admitted to the intensive care unit (ICU) of Zunyi Medical University Affiliated Hospital (Zhuhai). The sputum specimens were collected for RSV testing, and the clinical data were collected and analyzed statistically.</p><p><strong>Results: </strong>The findings revealed that patients in the RSV-positive group were older, had a higher prevalence of underlying diseases, were more likely to require noninvasive mechanical ventilation, and had prolonged hospital stays compared with those in the RSV-negative group. Furthermore, Kaplan-Meier survival analysis conducted within 90 days revealed comparable mortality rates between the RSV-positive and RSV-negative groups. In the RSV-positive group, elderly patients and patients with congestive heart failure or chronic obstructive pulmonary disease had lower survival rates.</p><p><strong>Conclusion: </strong>Patients in the RSV-positive group, particularly elderly patients and patients with congestive heart failure or, experience reduced survival durations compared with those in the RSV-negative group.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"184"},"PeriodicalIF":2.6,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12007204/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143958676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}